Download PDF
Laryngorhinootologie
DOI: 10.1055/a-2468-6211
Originalarbeit

Diagnostik, Therapie und onkologisches Outcome bei zervikalen CUP-Syndromen je nach p16-Status

Diagnosis, treatment and oncological outcome of cervical CUP-syndrome depending on p16 status
Lukas Boosfeld
1   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Essen, Essen, Deutschland (Ringgold ID: RIN39081)
,
Stephan Lang
1   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Essen, Essen, Deutschland (Ringgold ID: RIN39081)
,
Stefan Mattheis
1   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Essen, Essen, Deutschland (Ringgold ID: RIN39081)
,
Micheal Peis
1   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Essen, Essen, Deutschland (Ringgold ID: RIN39081)
,
Gregor Zaun
2   Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany
,
Sebastian Waßenberg
3   Diplom-Psychologe, Punkt05 Statistikberatung, Düsseldorf, Germany
,
Hideo Andreas Baba
4   Institut für Pathologie, Universitätsklinikum Essen, Essen, Germany (Ringgold ID: RIN39081)
,
Timon Hussain
5   Klinik für Hals-, Nasen-, Ohrenheilkunde, Klinikum rechts der Isar der Technischen Universität München, München, Germany (Ringgold ID: RIN27190)
,
Cornelius Kürten
1   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Essen, Essen, Deutschland (Ringgold ID: RIN39081)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Einleitung

Die Inzidenz zervikaler Plattenepithel (SCC)-CUP-Syndrome steigt mit einem relevanten HPV-assoziierten Anteil. In dieser 10 Jahre umfassenden retrospektiven Studie wurden klinische und therapeutische Parameter von Patienten mit zervikalen SCC-CUP erfasst. Neben einer Analyse der Primärtumordetektionsrate bei initialem SCC-CUP (SCC-CUPinit) wurde das mittlere Gesamtüberleben sowie das rezidivfreie Überleben bei Patienten ohne Primärtumordetektion nach erweiterter Diagnostik, also definitiven SCC-CUP (SCC-CUPdef), in Abhängigkeit vom p16-Status ausgewertet, um therapeutische Empfehlungen abzuleiten.

Ergebnisse

Bei 85% (n=131/155) der CUPinit handelte es sich histologisch um SCC, gefolgt von Adenokarzinommetastasen bei 7% (n=10/155). Bei 41% (n=54/131) der Patienten mit SCC-CUPinit wurde mittels erweiterter Diagnostik ein Primärtumor identifiziert; die Primärtumordetektionsrate war dabei bei p16-positiven vs. p16-negativen signifikant höher (63% vs. 23%, p<0,001). Die PET-Bildgebung wies eine Sensitivität bzw. Spezifität von je 73% auf. SCC-CUPdef wurden vorrangig primär chirurgisch mit adjuvanter Radio(chemo)therapie behandelt, SCC-CUPdef-Patienten mit positivem vs. negativem p16-Status wiesen ein signifikant längeres Gesamtüberleben auf (53 vs. 41 Monate, p=0,037), ebenso Patienten mit cN1- vs. cN3-Status und M0- vs. M1-Status.

Fazit

Der p16-Status beeinflusst bei Patienten mit SCC-CUP die Diagnostik und Therapie: Bei p16-positiven SCC-CUPinit gelang signifikant häufiger eine Primärtumordetektion als bei p16-negativen SCC-CUPinit. Bei Patienten mit SCC-CUPdef war ein positiver p16-Status mit einem besserem Gesamtüberleben assoziiert, die Unterschiede rechtfertigen jedoch bislang keine Therapiedeeskalation.

Abstract

Introduction

The incidence of cervical squamous cell carcinoma (SCC)-CUP is increasing, with a significant proportion being HPV-associated. In this 10-year retrospective study, we analyzed clinical and therapeutic parameters of patients with cervical SCC-CUP. Primary tumor detection rates in patients with initial SCC-CUP (SCC-CUPinit) were assessed and mean overall survival and disease-free survival of patients without primary tumor detection after an extended diagnostic workup, i.e. definitive SCC-CUP (SCC-CUPdef), were analyzed taking p16-status into account to derive therapeutic recommendations.

Results

85% (n=131/155) of patients with CUPinit, presented with SCC followed by adenocarcinoma metastases in 7% (n=10/155). In 41% (n=54/131) of patients with SCC-CUPinit, a primary tumor was identified after an extended diagnostic workup; the primary tumor detection rate was significantly higher in p16-positive compared to p16-negative cases (63% vs. 23%, p<0,001). PET imaging specificity was 73% for both sensitivity and specificity. SCC-CUPdef were primarily treated surgically with adjuvant radio(chemo)therapy. SCC-CUPdef patients with positive vs. negative p16-status had significantly longer overall survival (53 vs. 41 Monate, p=0,037), as well as patients with cN1- vs. cN3-status and M0- vs. M1-status.

Conclusion

p16-status influences diagnosis and therapy response in patients with SCC-CUP: in p16-positive SCC-CUPinit, primary tumor detection rates were significantly higher than in p16-negative SCC-CUPinit. In patients with SCC-CUPdef, p16-positivity was associated with improved overall survival, albeit to an extent which does not justify therapy de-escalation.

Schlüsselwörter

zervikales CUP-Syndrom - Plattenepithelkarziom des Kopf-Hals-Bereichs - p16-Status - Therapie - Prognose

Keywords

CUP syndrome - HNSCC - p16-status

Zusatzmaterial



Publication History

Received: 05 June 2024

Accepted after revision: 13 November 2024

Article published online:
05 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Kennel T, Garrel R, Costes V. et al. Head and neck carcinoma of unknown primary. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136: 185-192
    CrossrefPubMedSearch in Google Scholar
  • 2 Rassy E, Nicolai P, Pavlidis N. Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. Head Neck 2019; 41: 3700-3711
    CrossrefPubMedSearch in Google Scholar
  • 3 Cummings MA, Ma SJ, Sloot PVD. et al. Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry. Annals of Translational Medicine 2021; 9: 284
    CrossrefPubMedSearch in Google Scholar
  • 4 Barsouk A, Aluru JS, Rawla P. et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel) 2023; 11
    CrossrefPubMedSearch in Google Scholar
  • 5 Al Kadah B, Papaspyrou G, Linxweiler M. et al. Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients. European Archives of Oto-Rhino-Laryngology 2017; 274: 2557-2566
    CrossrefPubMedSearch in Google Scholar
  • 6 Donta TS, Smoker WR. Head and neck cancer: carcinoma of unknown primary. Top Magn Reson Imaging 2007; 18: 281-292
    CrossrefPubMedSearch in Google Scholar
  • 7 Mistry R, Walker A, Kim D. et al. Transoral robotic surgery for the benefit of patients with head and neck cancer of unknown primary: our experience at St George’s University Hospital, London. Ann R Coll Surg Engl 2020; 102: 442-450
    CrossrefPubMedSearch in Google Scholar
  • 8 Cho WK, Roh JL, Cho KJ. et al. Predictors of survival and recurrence after primary surgery for cervical metastasis of unknown primary. J Cancer Res Clin Oncol 2020; 146: 925-933
    CrossrefPubMedSearch in Google Scholar
  • 9 Guntinas-Lichius O, Peter Klussmann J, Dinh S. et al. Diagnostic work-up and outcome of cervical metastases from an unknown primary. Acta Otolaryngol 2006; 126: 536-544
    CrossrefPubMedSearch in Google Scholar
  • 10 Kalavacherla S, Sanghvi P, Lin GY. et al. Updates in the management of unknown primary of the head and neck. Front Oncol 2022; 12: 991838
    CrossrefPubMedSearch in Google Scholar
  • 11 Maghami E, Ismaila N, Alvarez A. et al. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. Journal of Clinical Oncology 2020; 38: 2570-2596
    CrossrefPubMedSearch in Google Scholar
  • 12 Tanzler ED, Amdur RJ, Morris CG. et al. Challenging the need for random directed biopsies of the nasopharynx, pyriform sinus, and contralateral tonsil in the workup of unknown primary squamous cell carcinoma of the head and neck. Head Neck 2016; 38: 578-581
    CrossrefPubMedSearch in Google Scholar
  • 13 Golusinski P, Di Maio P, Pehlivan B. et al. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol 2019; 88: 145-152
    CrossrefPubMedSearch in Google Scholar
  • 14 Lee MY, Fowler N, Adelstein D. et al. Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin. Anticancer Res 2020; 40: 4207-4214
    CrossrefPubMedSearch in Google Scholar
  • 15 Cheraghlou S, Torabi SJ, Husain ZA. et al. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. Laryngoscope 2019; 129: 684-691
    CrossrefPubMedSearch in Google Scholar
  • 16 Meulemans J, Voortmans J, Nuyts S. et al. Cervical squamous cell carcinoma of unknown primary: Oncological outcomes and prognostic factors. Front Oncol 2022; 12: 1024414
    CrossrefPubMedSearch in Google Scholar
  • 17 Wagner S, Langer C, Wuerdemann N. et al. Predictors for Survival of Patients with Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Region. Cancers (Basel) 2023; 15 (07) 2167
    CrossrefPubMedSearch in Google Scholar
  • 18 Lechner M, Liu J, Masterson L. et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022; 19: 306-327
    CrossrefPubMedSearch in Google Scholar
  • 19 Ziegler A, Lange S, Bender R. Survival analysis: log rank test. Dtsch Med Wochenschr 2007; 132: e39-41
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Ostojewska J, Wieczorek I, Pachciński O. et al. Detecting undetectable – epidemiology, etiology, and diagnosis of carcinoma of unknown primary – systematic review. Folia Med Cracov 2023; 63: 19-37
    CrossrefPubMedSearch in Google Scholar
  • 21 Carlander AF, Jakobsen KK, Bendtsen SK. et al. A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide. Viruses 2021; 13
    CrossrefPubMedSearch in Google Scholar
  • 22 Mehanna H, Taberna M, von Buchwald C. et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol 2023; 24: 239-251
    CrossrefPubMedSearch in Google Scholar
  • 23 Al-Lami A, Gao C, Saddiq M. et al. Reducing the unknowns: A systematic review & meta-analysis of the effectiveness of trans-oral surgical techniques in identifying head and neck primary cancer in carcinoma unknown primary. Oral Oncol 2022; 126: 105748
    CrossrefPubMedSearch in Google Scholar
  • 24 Patel SA, Parvathaneni A, Parvathaneni U. et al. Post-operative therapy following transoral robotic surgery for unknown primary cancers of the head and neck. Oral Oncol 2017; 72: 150-156
    CrossrefPubMedSearch in Google Scholar
  • 25 Ryan JF, Motz KM, Rooper LM. et al. The Impact of a Stepwise Approach to Primary Tumor Detection in Squamous Cell Carcinoma of the Neck With Unknown Primary. Laryngoscope 2019; 129: 1610-1616
    CrossrefPubMedSearch in Google Scholar
  • 26 Schroeder L, Pring M, Ingarfield K. et al. HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer. Oral Oncol 2020; 107: 104721
    CrossrefPubMedSearch in Google Scholar
  • 27 Podeur P, Mancini J, Delgrande J. et al. Role of Tonsillectomy in the Management of Carcinomas of Unknown Primary of the Head and Neck: A Retrospective Study Based on p16 Analysis. Front Oncol 2020; 10: 594168
    CrossrefPubMedSearch in Google Scholar
  • 28 Albertson M, Chandra S, Sayed Z. et al. PET/CT Evaluation of Head and Neck Cancer of Unknown Primary. Semin Ultrasound CT MR 2019; 40: 414-423
    CrossrefPubMedSearch in Google Scholar
  • 29 Strojan P, Ferlito A, Langendijk JA. et al. Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 2013; 35: 286-293
    CrossrefPubMedSearch in Google Scholar
  • 30 Oebel L, Mayer A, Kaufmann J. et al. Is bilateral radiotherapy necessary for patients with unilateral squamous cell carcinoma of unknown primary of the head and neck region?. Clin Transl Radiat Oncol 2024; 45: 100713
    CrossrefPubMedSearch in Google Scholar
  • 31 Kamal M, Mohamed ASR, Fuller CD. et al. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer 2018; 124: 1415-1427
    CrossrefPubMedSearch in Google Scholar